Library Subscription: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

Published 6 issues per year

ISSN Print: 0743-4863

ISSN Online: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Newer Therapeutic Vistas for Antiglaucoma Medicines

Volume 28, Issue 2, 2011, pp. 165-202
DOI: 10.1615/CritRevTherDrugCarrierSyst.v28.i2.20
Get accessGet access

ABSTRACT

Glaucoma is second to cataract as a leading cause of global blindness and is the leading cause of irreversible visual loss. By the year 2020, almost 80 million people are estimated to be affected with open-angle glaucoma and angle-closure glaucoma. Sufficiently high concentrations of a free drug should be achieved within the aqueous humor and at the iris/ciliary body for sufficiently illustrating an antiglaucoma effect. Most drug groups including cholinergic agents, prostaglandin analogs, and carbonic anhydrase inhibitors being used in glaucoma were initially developed for other effects or routes and later found their use in the control of glaucoma. Hence, these molecules are not tailor made for delivery into the eye. Discovery of new molecules requires at least 15−20 years; hence, it may be concluded that instead of abandoning the existing molecules. It may be worthwhile to apply a novel drug-delivery approach to enhance ocular bioavailability and reduce systemic side effects of currently used agents. This review will elaborate on the potential to pharmaceutically tailor existing antiglaucoma agents using approaches including liposomes, collagen shields, dendrimers, in situ forming gels, and micro- and nanoparticles for achieving improved ocular effectiveness. Further to this, a preliminary discussion on miscellaneous agents such as siRNA, peptides, antioxidants and nitric oxide−releasing agents that are recently being proposed for the relief of glaucoma is also covered.

CITED BY
  1. Mittal Neeraj, Kaur Gurpreet, In situgelling ophthalmic drug delivery system: Formulation and evaluation, Journal of Applied Polymer Science, 131, 2, 2014. Crossref

  2. Mishra Vijay, Jain N.K., Acetazolamide encapsulated dendritic nano-architectures for effective glaucoma management in rabbits, International Journal of Pharmaceutics, 461, 1-2, 2014. Crossref

  3. Kakkar Shilpa, Karuppayil Sankunny Mohan, Raut Jayant S., Giansanti Fabrizio, Papucci Laura, Schiavone Nicola, Kaur Indu Pal, Lipid-polyethylene glycol based nano-ocular formulation of ketoconazole, International Journal of Pharmaceutics, 495, 1, 2015. Crossref

  4. Ribeiro Andreza, Neumann Ivan, Advances in Composite Hydrogels for Ocular Drug Delivery and Biomedical Engineering Application, in Functional Hydrogels in Drug Delivery, 2017. Crossref

  5. Mittal Neeraj, Kaur Gurpreet, Leucaena leucocephala (Lam.) galactomannan nanoparticles: Optimization and characterization for ocular delivery in glaucoma treatment, International Journal of Biological Macromolecules, 139, 2019. Crossref

  6. Mohsen Amira Mohamed, Salama Abeer, Kassem Ahmed Alaa, Development of acetazolamide loaded bilosomes for improved ocular delivery: Preparation, characterization and in vivo evaluation, Journal of Drug Delivery Science and Technology, 59, 2020. Crossref

  7. Park Chun Gwon, Choi Goeun, Kim Myung Hun, Kim Se-Na, Lee Hanna, Lee Na Kyeong, Choy Young Bin, Choy Jin-Ho, Brimonidine–montmorillonite hybrid formulation for topical drug delivery to the eye, Journal of Materials Chemistry B, 8, 35, 2020. Crossref

  8. Tiwari Rahul, Sethiya Neeraj K., Gulbake Anamika Sahu, Mehra Neelesh Kumar, Murty U.S.N., Gulbake Arvind, A review on albumin as a biomaterial for ocular drug delivery, International Journal of Biological Macromolecules, 191, 2021. Crossref

  9. Park Chun Gwon, Kim Young Kook, Kim Mi Jeung, Park Min, Kim Myung Hun, Lee Seung Ho, Choi Sung Yoon, Lee Won Seok, Chung You Jung, Jung Young Eun, Park Ki Ho, Choy Young Bin, Mucoadhesive microparticles with a nanostructured surface for enhanced bioavailability of glaucoma drug, Journal of Controlled Release, 220, 2015. Crossref

Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections Prices and Subscription Policies Begell House Contact Us Language English 中文 Русский Português German French Spain